Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys. / Madsen, Morten V; Peacock, Linda P; Werge, Thomas; Andersen, Maibritt Højgaard; Andreasen T., Jesper.

In: Neuropharmacology, Vol. 60, No. 2-3, 2011, p. 418-22.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Madsen, MV, Peacock, LP, Werge, T, Andersen, MH & Andreasen T., J 2011, 'Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys', Neuropharmacology, vol. 60, no. 2-3, pp. 418-22. https://doi.org/10.1016/j.neuropharm.2010.10.014

APA

Madsen, M. V., Peacock, L. P., Werge, T., Andersen, M. H., & Andreasen T., J. (2011). Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys. Neuropharmacology, 60(2-3), 418-22. https://doi.org/10.1016/j.neuropharm.2010.10.014

Vancouver

Madsen MV, Peacock LP, Werge T, Andersen MH, Andreasen T. J. Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys. Neuropharmacology. 2011;60(2-3):418-22. https://doi.org/10.1016/j.neuropharm.2010.10.014

Author

Madsen, Morten V ; Peacock, Linda P ; Werge, Thomas ; Andersen, Maibritt Højgaard ; Andreasen T., Jesper. / Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys. In: Neuropharmacology. 2011 ; Vol. 60, No. 2-3. pp. 418-22.

Bibtex

@article{48a1049fdeb84a7096b6aac2c13c2c71,
title = "Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys",
abstract = "Antipsychotic drugs may cause extrapyramidal symptoms (EPS), such as dyskinesia and dystonia. These effects are believed to involve dysfunctional striatal dopamine transmission. Patients with schizophrenia show increased prevalence of cannabis abuse and this has been linked to severity of EPS. Endocannabinoids modulate striatal dopamine activity via type 1 cannabinoid (CB(1)) receptors, and studies in rats and humans suggest beneficial effects of CB(1) ligands on EPS. The present study explored the effects of CB(1) receptor ligands on oral dyskinesia induced by the dopamine D(1) receptor agonist SKF81297 (SKF) and acute dystonia induced by the dopamine D(2) receptor antagonist haloperidol in Cebus apella monkeys. The monkeys were sensitised to EPS by prior exposure to D(2) receptor antagonists. SKF (0.3 mg/kg) was administered alone and in combination with the CB(1) agonist CP55,940 (0.0025-0.01 mg/kg) or the CB(1) antagonist SR141716A (0.25-0.75 mg/kg). Haloperidol (individual doses at 0.01-0.02 mg/kg) was administered alone and in combination with CP55,940 (0.005 or 0.01 mg/kg) or SR141716A (0.5 or 0.75 mg/kg). Subsequently, the monkeys were videotaped, and the recordings were rated for oral dyskinesia or dystonia. SKF-induced oral dyskinesia was dose-dependently reduced by CP55,940, with no effect of SR141716A. Haloperidol-induced dystonia was not affected by either CP55,940 or SR141716A.",
keywords = "Former Faculty of Pharmaceutical Sciences",
author = "Madsen, {Morten V} and Peacock, {Linda P} and Thomas Werge and Andersen, {Maibritt H{\o}jgaard} and {Andreasen T.}, Jesper",
note = "Copyright {\circledC} 2010 Elsevier Ltd. All rights reserved.",
year = "2011",
doi = "10.1016/j.neuropharm.2010.10.014",
language = "English",
volume = "60",
pages = "418--22",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Pergamon Press",
number = "2-3",

}

RIS

TY - JOUR

T1 - Effects of cannabinoid CB(1) receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys

AU - Madsen, Morten V

AU - Peacock, Linda P

AU - Werge, Thomas

AU - Andersen, Maibritt Højgaard

AU - Andreasen T., Jesper

N1 - Copyright © 2010 Elsevier Ltd. All rights reserved.

PY - 2011

Y1 - 2011

N2 - Antipsychotic drugs may cause extrapyramidal symptoms (EPS), such as dyskinesia and dystonia. These effects are believed to involve dysfunctional striatal dopamine transmission. Patients with schizophrenia show increased prevalence of cannabis abuse and this has been linked to severity of EPS. Endocannabinoids modulate striatal dopamine activity via type 1 cannabinoid (CB(1)) receptors, and studies in rats and humans suggest beneficial effects of CB(1) ligands on EPS. The present study explored the effects of CB(1) receptor ligands on oral dyskinesia induced by the dopamine D(1) receptor agonist SKF81297 (SKF) and acute dystonia induced by the dopamine D(2) receptor antagonist haloperidol in Cebus apella monkeys. The monkeys were sensitised to EPS by prior exposure to D(2) receptor antagonists. SKF (0.3 mg/kg) was administered alone and in combination with the CB(1) agonist CP55,940 (0.0025-0.01 mg/kg) or the CB(1) antagonist SR141716A (0.25-0.75 mg/kg). Haloperidol (individual doses at 0.01-0.02 mg/kg) was administered alone and in combination with CP55,940 (0.005 or 0.01 mg/kg) or SR141716A (0.5 or 0.75 mg/kg). Subsequently, the monkeys were videotaped, and the recordings were rated for oral dyskinesia or dystonia. SKF-induced oral dyskinesia was dose-dependently reduced by CP55,940, with no effect of SR141716A. Haloperidol-induced dystonia was not affected by either CP55,940 or SR141716A.

AB - Antipsychotic drugs may cause extrapyramidal symptoms (EPS), such as dyskinesia and dystonia. These effects are believed to involve dysfunctional striatal dopamine transmission. Patients with schizophrenia show increased prevalence of cannabis abuse and this has been linked to severity of EPS. Endocannabinoids modulate striatal dopamine activity via type 1 cannabinoid (CB(1)) receptors, and studies in rats and humans suggest beneficial effects of CB(1) ligands on EPS. The present study explored the effects of CB(1) receptor ligands on oral dyskinesia induced by the dopamine D(1) receptor agonist SKF81297 (SKF) and acute dystonia induced by the dopamine D(2) receptor antagonist haloperidol in Cebus apella monkeys. The monkeys were sensitised to EPS by prior exposure to D(2) receptor antagonists. SKF (0.3 mg/kg) was administered alone and in combination with the CB(1) agonist CP55,940 (0.0025-0.01 mg/kg) or the CB(1) antagonist SR141716A (0.25-0.75 mg/kg). Haloperidol (individual doses at 0.01-0.02 mg/kg) was administered alone and in combination with CP55,940 (0.005 or 0.01 mg/kg) or SR141716A (0.5 or 0.75 mg/kg). Subsequently, the monkeys were videotaped, and the recordings were rated for oral dyskinesia or dystonia. SKF-induced oral dyskinesia was dose-dependently reduced by CP55,940, with no effect of SR141716A. Haloperidol-induced dystonia was not affected by either CP55,940 or SR141716A.

KW - Former Faculty of Pharmaceutical Sciences

U2 - 10.1016/j.neuropharm.2010.10.014

DO - 10.1016/j.neuropharm.2010.10.014

M3 - Journal article

C2 - 21029743

VL - 60

SP - 418

EP - 422

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 2-3

ER -

ID: 34179838